Replies to post #24918 on Marker Therapeutics Inc (MRKR)

[Tripolar]

Hanscott,

Unfortunately, the main reason I think this is because the survival rate for ovarian patients is much lower than for TNBC patients. The five year survival rate is 77 percent for TNBC and 47 percent for ovarian. I believe the ovarian studies would mature sooner than the TNBC studies.
A secondary reason I think this is that if the MSK combo study with AZN's Imfinzi is successful, we'll have a strong partner to help move things along with the FDA.
P.H. stated in a PR prior to the merger that he thought the ovarian vaccine could be available by 2022. This assumes that they still want to move forward with the peptide vaccines.